Key result
Peripheral CB1R inhibition ameliorates diet-induced cardiac hypertrophy and metabolic dysfunction in mice.
Why the study?
Obesity-related cardiac remodeling involves cardiomyocyte hypertrophy and fibrosis leading to heart failure, and CB1R activation is implicated in metabolic and cardiovascular dysfunction.
Does inhibition of peripheral CB1R signaling attenuate high-fat, high-sugar diet-induced cardiometabolic dysfunction in mice?
Does inhibition of peripheral CB1R signaling attenuate high-fat, high-sugar diet-induced cardiometabolic dysfunction in mice?
Hypothesis-generating for peripheral CB1R blockade in obesity cardiomyopathy; leaves open human translation and clinical testing.
Objectives: Obesity is associated with cardiac remodeling characterized by cardiomyocyte hypertrophy and fibrosis, which can ultimately progress to heart failure. Activation of cannabinoid 1 receptor (CB1R) has been implicated in metabolic dysfunction and cardiovascular pathology. This study aimed to determine whether inhibition of peripheral CB1R signaling attenuates high-fat, high-sugar diet (HFHSD)–induced cardiometabolic dysfunction in mice.
No takes yet. Share an insight, caveat, or question.
Lamichhane et al. (2026) studied High-fat, high-sugar diet-induced cardiometabolic dysfunction. Inhibition of peripheral Cannabinoid 1 Receptor (CB1R) was evaluated. Inhibition of peripheral Cannabinoid 1 Receptor (CB1R) ameliorated high-fat, high-sugar diet-induced cardiac hypertrophy and metabolic dysfunction in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: